To confirm that the tumor-promoting effect of IKBIP was achieved by the activation of the AKT pathway, we used LY294002 (10 μg/mL), a specific inhibitor of the PI3K/AKT signaling pathway, to treat KYSE-150 cells with IKBIP overexpression (OE) and their matched control cells (Vector). This evidence concerns the gene AKT1 and neoplasm.